- In January 2024, Amneal Pharmaceuticals announced the successful launch of 39 new retail and injectable products throughout 2023, with 13 introduced in the fourth quarter alone. This strategic expansion highlights Amneal's dedication to diversifying its product portfolio and addressing the growing demand for innovative drug delivery solutions. The company's initiatives are aimed at providing healthcare providers and patients with a broader selection of therapeutic options, contributing to the continued growth and development of the global injectable drug delivery market
- In January 2024, Kindeva Drug Delivery announced the acquisition of Summit Biosciences, a leader in nasal drug development and manufacturing. This strategic acquisition strengthens Kindeva’s position in the nasal drug delivery segment, expanding its product portfolio and enhancing its capabilities in delivering innovative therapies. The move is designed to accelerate product development and address the increasing demand for effective nasal drug delivery solutions, contributing to the overall growth of the global injectable drug delivery market
- In July 2024, Schott AG launched new 10ml ready-to-use cartridges intended for the storage of medications targeting a range of diseases, including cancer, genetic disorders, metabolic conditions, cardiovascular diseases, and immunological disorders. These cartridges are designed to be compatible with Ypsomed's YpsoDose device, facilitating a pre-filled and pre-loaded system that enables easier self-administration by patients at home. This innovation aligns with the growing demand for convenient and efficient drug delivery solutions, further contributing to the expansion of the global injectable drug delivery market by enhancing patient convenience and supporting the shift towards home-based therapies
- In April 2024, Baxter announced the expansion of its product portfolio in the U.S., introducing five new injectable medications, including pre-filled syringes and ready-to-use intravenous solutions. These products are designed to meet unmet medical needs in critical areas such as anti-infective and anti-hypotensive treatments. This expansion underscores Baxter's commitment to advancing the injectable drug delivery market by providing healthcare providers with efficient, ready-to-use solutions that improve patient care and streamline treatment administration, supporting the overall growth of the global injectable drug delivery market
- In January 2022, West Pharmaceutical Services announced a strategic partnership with Corning to advance pharmaceutical injectable drug delivery systems. This collaboration combines the strengths of both companies in developing innovative solutions designed to ensure the safe and efficient administration of injectable medications. The partnership is expected to foster significant advancements in the pharmaceutical sector, enhancing patient outcomes and optimizing drug delivery processes, thereby contributing to the continued growth and innovation within the global injectable drug delivery market
Frequently Asked Questions
One prominent trend in the evolution of injectable drug delivery systems is the increasing integration of smart technologies such as auto-injectors and wearable devices that improve patient adherence and reduce the need for healthcare professional intervention.
The increasing prevalence of chronic diseases such as diabetes, cancer, rheumatoid arthritis, and cardiovascular diseases is significantly driving the demand for injectable drug delivery systems.
The injectable drug delivery market faces significant challenges due to stringent regulatory requirements and compliance hurdles, particularly in the approval and commercialization of new devices and therapies.
The injectable drug delivery formulation segment is expected to dominate the global injectable drug delivery market holding a major market share of 58% due to the increasing prevalence of chronic diseases, increasing adaption of self-injection and the rising demand for biologics.
The Asia-Pacific region is expected to witness the highest growth rate in the injectable drug delivery market, driven by rapid advancements in healthcare infrastructure, increasing healthcare access, and rising demand for injectable biologics and vaccines.
